
March 7 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS ANNOUNCES 33% ENROLLMENT IN SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA
BIOXCEL THERAPEUTICS INC: TOPLINE DATA EXPECTED IN SECOND HALF OF 2025
BIOXCEL THERAPEUTICS: SERENITY PHASE 3 SAFETY TRIAL TOPLINE DATA EXPECTED IN H2 2025